Fig 1: Associations of B7-H2 and B7-H3 with survival and recurrence rates. Kaplan-Meier analysis of the association between the expression of B7-H2 or B7-H3 and (A) overall survival rate and (B) cumulative recurrence in patients with hepatocellular carcinoma.
Fig 2: Kaplan-Meier analysis of the association between survival rate and the combined expression of B7-H2 and B7-H3 in patients with hepatocellular carcinoma. (A) Comparison between the overall survival rate of patients and the expression of B7-H2 and B7-H3. (B) Comparison of overall survival rate between B7-H2-/B7-H3- patients and B7-H2+/B7-H3+ or B7-H2+/B7-H3- or B7-H2-/B7-H3+ patients.
Fig 3: Potential correlation between B7-H3, B7-H4, HHLA2, and clinicopathological factors in patients with GBC. There were significant interrelationships between B7-H3, B7-H4, and HHLA2 in both the (A) training group and the (B) testing group. Different expression levels (high/low) of B7-H3, B7-H4, and HHLA2 were significantly associated with pathological stages, clinical and surgical parameters, and prognostic survival. (*p < 0.05, **p = 0.01, ***p = 0.001; blank, no significance.).
Fig 4: Receiver operating characteristic analysis of the combined expression of B7-H2 and B7-H3 for indicating the survival rate of patients with HCC. (A) AUC for the combined expression of B7-H3 and B7-H2 in patients with HCC. (B) AUC for the expression of AFP in patients with HCC. (C) Confirmation of overall survival prediction in patients with HCC by the combined expression of B7-H3 and B7-H2 by Kaplan-Meier analysis. (D) Kaplan-Meier analysis of cumulative recurrence prediction in patients with HCC by the combination expression of B7-H3 and B7-H2. AUC, area under the curve; AFP, a-fetoprotein; HCC, hepatocellular carcinoma; CI, confidence interval; PI, prognostic indicator.
Fig 5: B7-H3, B7-H4, and HHLA2 expression in gallbladder (GBC) tissue. (A) Immunohistochemical staining of B7-H3, B7-H4, and HHLA2 in GBC tissues is presented separately. The degree of staining intensity was graded as follows: negative staining, 0; weak staining, 1; moderate staining, 2; and strong staining, 3. Scale bar, 50 µm. (B, C) The proportion of GBC patients in different co-expression patterns of the B7-third group (B7-H3, B7-H4, and HHLA2) in the training and testing groups, respectively.
Supplier Page from Abcam for Anti-CD276 antibody [6A1]